Skip to main content

Table 8 Noncarrier study exploratory clinical efficacy assessments: change from parent study baseline to extension week 52

From: Long-term safety and tolerability of bapineuzumab in patients with Alzheimer’s disease in two phase 3 extension studies

  3002 ApoE ε4 noncarrier study
PBO + BAP 0.5 (n = 38) BAP 0.5 + BAP 0.5 (n = 62) PBO + BAP 1.0 (n = 33) BAP 1.0 + BAP 1.0 (n = 53)
ADAS-Cog, LS mean (SE) 12.44 (1.70) 10.38 (1.35) 10.54 (1.82) 10.31 (1.36)
 LS mean difference –2.05; P = 0.345 –0.22; P = 0.922
DAD, LS mean (SE) –29.52 (3.48) –28.00 (2.77) –20.41 (3.74) –23.21 (2.80)
 LS mean difference 1.53; P = 0.733 –2.81; P = 0.550
NPI, LS mean (SE) 4.99 (2.60) –0.01 (2.05) 4.23 (2.80) 6.57 (2.08)
 LS mean difference –4.99; P = 0.133 2.34; P = 0.505
MMSEa, LS mean (SE) –4.86 (0.56) –4.13 (0.44) –4.63 (0.58) –4.51 (0.46)
 LS mean difference 0.73; P = 0.309 0.12; P = 0.872
  1. ADAS-Cog Alzheimer’s Disease Assessment Scale—Cognitive Subscale, ApoE apolipoprotein E, BAP bapineuzumab, DAD Disability Assessment Scale for Dementia, LS least squares, MMSE Mini-Mental State Examination, NPI Neuropsychiatric Inventory, PBO placebo, SE standard error of the mean
  2. aDifference in MMSE score was between parent study baseline and extension study week 45